The IPO Buzz: Thyroid-Focused Septerna Sets Terms & Launches $175 Million IPO
Septerna Inc. (SEPN Proposed), a Phase 1 biotech focused on developing an oral drug to treat hypoparathyroidism, a rare endocrine disease, unveiled the terms for its $175 million IPO early today – Monday, Oct. 21, 2024. Septerna is offering 10.94 million shares at a price range of $15.00 to $17.00 to raise $175.0 million, if […]
October 21, 2024 Read More